Reported about 9 hours ago
Vertex Pharmaceuticals' stock has seen a significant increase following the FDA's approval of Journavx, a new non-opioid medication aimed at treating moderate to severe acute pain. This innovative drug offers a promising alternative to traditional opioid treatments, marking a noteworthy development in pain management.
Source: YAHOO